Article thumbnail

EGFR inhibition leads to actin cytoskeleton reorganization through Rho GTPase modulation.

By Guillem Ramis (320318), Elena Thomàs-Moyà (320319), Silvia Fernández de Mattos (320320), José Rodríguez (3463523) and Priam Villalonga (320321)


<p>(A) Representative phase-contrast micrographs of U87MG cells left untreated (control) or treated for 24 h with 10 µM erlotinib (erlotinib). (B) U87MG cells grown on coverslips were left untreated (control) or were treated for 24 h with 10 µM erlotinib (erlotinib), fixed and stained with TRITC-labelled phalloidin. Bar, 5 µm. (C) U87MG cells were treated as indicated, harvested and RhoA and Rac1 activation were analyzed by GST-Rhotekin and GST-PBD pulldown, respectively, followed by western blotting with anti-RhoA and anti-Rac1 antibodies (upper panel). An aliquot of each lysate was also loaded in another gel to analyze total RhoA and total Rac1 levels (bottom panel). The graphs represent the quantified mean ± SD Rho/Rac activation values (Rho-GTP/Total Rho and Rac-GTP/Total Rac), relative to untreated cells, from three independent experiments.</p

Topics: Molecular Biology, Cancer, inhibition, leads, actin, cytoskeleton, reorganization, rho, gtpase
Year: 2013
DOI identifier: 10.1371/journal.pone.0038770.g005
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.